Literature DB >> 9144119

Five-year follow-up of high-risk infants with family history of allergy who were exclusively breast-fed or fed partial whey hydrolysate, soy, and conventional cow's milk formulas.

R K Chandra1.   

Abstract

BACKGROUND: Allergy is a common cause of illness. The effect of feeding different infant formulas on the incidence of atopic disease and food allergy was assessed in a prospective randomized double-blind study of high-risk infants with a family history of atopy.
METHODS: 216 high-risk infants whose mothers had elected not to breast-feed were randomized to receive exclusively a partial whey hydrolysate formula or a conventional cow's milk formula or a soy formula until 6 months of age. Seventy-two high risk infants breast-fed for > or = 4 months were also studied.
RESULTS: Follow-up until 5 years of age showed a significant lowering in the cumulative incidence of atopic disease in the breast-fed (odds ratio 0.422 [0.200-0.891]) and the whey hydrolysate (odds ratio 0.322 [0.159-0.653) groups, compared with the conventional cow's milk group. Soy formula was not effective (odds ratio 0.759 [0.384-1.501]). The occurrence of both eczema and asthma was lowest in the breast-fed and whey hydrolysate groups and was comparable in the cow's milk and soy groups. Similar significant differences were noted in the 18-60 month period prevalence of eczema and asthma. Eczema was less severe in the whey hydrolysate group compared with the other groups. Double-blind placebo-controlled food challenges showed a lower prevalence of food allergy in the whey hydrolysate group compared with the other formula groups.
CONCLUSIONS: Exclusive breast-feeding or feeding with a partial whey hydrolysate formula is associated with lower incidence of atopic disease and food allergy. This is a cost-effective approach to the prevention of allergic disease in children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144119     DOI: 10.1097/00005176-199704000-00005

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  19 in total

Review 1.  Clinical evidence: atopic eczema.

Authors:  C Charman
Journal:  BMJ       Date:  1999-06-12

Review 2.  Personalizing protein nourishment.

Authors:  David C Dallas; Megan R Sanctuary; Yunyao Qu; Shabnam Haghighat Khajavi; Alexandria E Van Zandt; Melissa Dyandra; Steven A Frese; Daniela Barile; J Bruce German
Journal:  Crit Rev Food Sci Nutr       Date:  2017-10-13       Impact factor: 11.176

Review 3.  Efficacy of screening immune system function in at-risk newborns.

Authors:  Christopher J Pavlovski
Journal:  Australas Med J       Date:  2014-07-31

Review 4.  NTP-CERHR expert panel report on the reproductive and developmental toxicity of soy formula.

Authors:  Karl K Rozman; Jatinder Bhatia; Antonia M Calafat; Christina Chambers; Martine Culty; Ruth A Etzel; Jodi A Flaws; Deborah K Hansen; Patricia B Hoyer; Elizabeth H Jeffery; James S Kesner; Sue Marty; John A Thomas; David Umbach
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2006-08

5.  A history of infant feeding.

Authors:  Emily E Stevens; Thelma E Patrick; Rita Pickler
Journal:  J Perinat Educ       Date:  2009

Review 6.  Food allergy.

Authors:  R K Chandra
Journal:  Indian J Pediatr       Date:  2002-03       Impact factor: 1.967

Review 7.  Infant formulas containing hydrolysed protein for prevention of allergic disease and food allergy.

Authors:  David A Osborn; John Kh Sinn; Lisa J Jones
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 8.  Allergens in atopic dermatitis.

Authors:  Y-S Dai
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

9.  WIC participation, breastfeeding practices, and well-child care among unmarried, low-income mothers.

Authors:  Pinka Chatterji; Jeanne Brooks-Gunn
Journal:  Am J Public Health       Date:  2004-08       Impact factor: 9.308

Review 10.  Cost of illness of atopic dermatitis in children: a societal perspective.

Authors:  Andrew S Kemp
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.